<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116868</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A01002-43</org_study_id>
    <nct_id>NCT02116868</nct_id>
  </id_info>
  <brief_title>Pupillary Reflex Measurement to Guide Intraoperative Analgesia During Laparoscopic Surgery</brief_title>
  <official_title>Usefulness of Pupillary Reflex on Remifentanil and Morphine Consumption During Laparoscopic Surgery. A Bicentric, Prospective, Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether analgesia guided by pupillary reflex during
      laparoscopic surgery is effective in opioid sparing (intraoperative remifentanil and
      postoperative morphine).This is a prospective, randomized, controlled study performed in two
      centers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For now, intraoperative analgesia remains hard to assess in the absence of reliable and
      validated analgesia monitor. The analysis of pupillary reflex is a new tool to assess
      analgesia during the intraoperative and postoperative period.

      During laparoscopic surgery, carbon dioxide insufflation that produce pneumoperitoneum may
      induce hemodynamics events such as tachycardia or hypertension. These events may be
      misleading or confusing. Actually, these events are mainly considered as insufficient
      analgesia. Thus, anesthesiologists deepen analgesia and/or anesthesia by increasing
      concentration of anesthetics or opioids. These inappropriate actions may induce hypotension
      and/or bradycardia especially in elderly patients. On the contrary, insufficient analgesia
      may exist in hypovolemic patients or in patients with neuromuscular blocking agents.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peroperative Remifentanil consumption</measure>
    <time_frame>From the start of anesthesia to the end of surgery (&lt;10 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hemodynamic events (hypertension, hypotension, tachycardia or bradycardia...)</measure>
    <time_frame>From the start of anesthesia to the end of surgery (&lt;10 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antihypertensive agents or vasopressors</measure>
    <time_frame>From the start of anesthesia to the end of surgery (&lt;10 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of fluid replacement</measure>
    <time_frame>From the start of anesthesia to the end of surgery (&lt;10 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>In the immediate postoperative period (&lt;4 hours)</time_frame>
    <description>Using verbal rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative nausea and vomiting (PONV)</measure>
    <time_frame>In the immediate postoperative period (&lt;4 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from extubation between the end of surgery and PACU admission</measure>
    <time_frame>In the immediate postoperative period (&lt;4 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in PACU</measure>
    <time_frame>From PACU admission to an ALDRETE score of 10 (&lt; 4 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate postoperative morphine consumption</measure>
    <time_frame>During postanesthetic care unit (PACU) stay (&lt;4 hours)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Scheduled Laparoscopic Surgery</condition>
  <arm_group>
    <arm_group_label>Pupillometry guided analgesia (PP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Analgesia is guided by pupillary reflex. The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed. Administration of antihypertensive drugs or vasopressors is also guided.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard practice (ST)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Anesthesia and analgesia is left to the discretion of the anesthesiologist in charge. The anesthesiologist is blinded to the results of pupillometry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pupillometry guided analgesia (PP)</intervention_name>
    <description>Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.</description>
    <arm_group_label>Pupillometry guided analgesia (PP)</arm_group_label>
    <other_name>Algiscan Neurolight</other_name>
    <other_name>Pupillometer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tailored remifentanil controlled infusion</intervention_name>
    <description>The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed</description>
    <arm_group_label>Pupillometry guided analgesia (PP)</arm_group_label>
    <other_name>Traget controlled infusion</other_name>
    <other_name>TCI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tailored antihypertensive drug administration</intervention_name>
    <description>Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.</description>
    <arm_group_label>Pupillometry guided analgesia (PP)</arm_group_label>
    <other_name>Esmolol</other_name>
    <other_name>Nicardipine</other_name>
    <other_name>Urapidil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists status 1 to 4

          -  Scheduled laparoscopic surgery

          -  Standardized anesthesia (TCI)

          -  Social security affiliation

        Exclusion Criteria:

          -  Age &lt; 18 yrs old

          -  Emergency

          -  BMI ≥ 35 kg.m-2

          -  Refusal of consent

          -  History of ocular pathology

          -  Intake of: metoclopramide, droperidol, opioids or substitutive therapies

          -  Patient with chronic pain

          -  Neurologic impairments

          -  Neuropathic pain

          -  Drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude MEISTELMAN, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology and Critical Care Medicine, CHU NANCY Brabois, FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe GUERCI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Critical Care Medicine, CHU NANCY Brabois, FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florence VIAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Maternité Régionale Universitaire, CHU NANCY, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé BOUAZIZ, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology, Maternité Regionale Universitaire, CHU NANCY, FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe GUERCI, MD.</last_name>
    <phone>+33 3 83 15 73 99</phone>
    <email>p.guerci@chu-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence VIAL, MD.</last_name>
    <phone>+ 33 3 83 34 43 67</phone>
    <email>f.vial@maternite.chu-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternité Régionale Universitaire (MRU)</name>
      <address>
        <city>Nancy</city>
        <state>Lorraine</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence VIAL, MD.</last_name>
      <phone>+33 3 83 34 44 67</phone>
      <email>f.vial@maternite.chu-nancy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hervé BOUAZIZ, MD., PhD.</last_name>
      <phone>+33 3 83 34 44 67</phone>
      <email>h.bouaziz@chu-nancy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Florence VIAL, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine HERBAIN, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire, Brabois</name>
      <address>
        <city>Nancy</city>
        <state>Lorraine</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe GUERCI, MD.</last_name>
      <phone>+33 3 83 15 73 99</phone>
      <email>p.guerci@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Denis SCHMARTZ, MD.</last_name>
      <phone>+33 3 83 15 74 82</phone>
      <email>d.schmartz@chu-nancy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe GUERCI, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis SCHMARTZ, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pupillometry</keyword>
  <keyword>Pupillary reflex</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Laparoscopic surgery</keyword>
  <keyword>Total intravenous anesthesia</keyword>
  <keyword>Target controlled infusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

